These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. Kessler KM; Humphries WC; Black M; Spann JF Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic properties of ethosuximide in monkeys. II. Chronic intravenous and oral administration. Patel IH; Levy RH Epilepsia; 1975 Dec; 16(5):717-30. PubMed ID: 816645 [TBL] [Abstract][Full Text] [Related]
48. Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. Fremstad D; Jacobsen S; Lunde KM Acta Pharmacol Toxicol (Copenh); 1977 Aug; 41(2):161-76. PubMed ID: 579055 [TBL] [Abstract][Full Text] [Related]
49. Effects of dihydroquinidine on in vitro and in vivo quinidine disposition. Ueda CT Biochem Pharmacol; 1980 Mar; 29(5):737-40. PubMed ID: 20227949 [TBL] [Abstract][Full Text] [Related]
50. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708 [TBL] [Abstract][Full Text] [Related]
51. The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Iven H Naunyn Schmiedebergs Arch Pharmacol; 1977 May; 298(1):43-50. PubMed ID: 882146 [TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. Rakhit A; Guentert TW; Holford NH; Verhoeven J; Riegelman S Eur J Drug Metab Pharmacokinet; 1984; 9(4):315-24. PubMed ID: 6532805 [TBL] [Abstract][Full Text] [Related]
54. Disposition of intravenous propylthiouracil. Giles HG; Roberts EA; Orrego H; Sellers EM J Clin Pharmacol; 1981; 21(11):466-71. PubMed ID: 7334138 [TBL] [Abstract][Full Text] [Related]
55. Acebutolol disposition after intravenous administration. Meffin PJ; Winkle RA; Peters FA; Harrison DC Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):557-67. PubMed ID: 913023 [TBL] [Abstract][Full Text] [Related]
56. Kinetics and dynamics of quinidine-N-oxide in healthy subjects. Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790 [TBL] [Abstract][Full Text] [Related]
57. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Munafo A; Buclin T; Tuto D; Biollaz J Eur J Clin Pharmacol; 1992; 43(4):441-3. PubMed ID: 1451729 [TBL] [Abstract][Full Text] [Related]
58. Comparative pharmacokinetics of quinidine and its O-desmethyl metabolite in rabbits. Ueda CT; Nickols JG J Pharm Sci; 1980 Dec; 69(12):1400-3. PubMed ID: 7463324 [TBL] [Abstract][Full Text] [Related]
59. The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. Mansor SM; Ward SA; Edwards G; Hoaksey PE; Breckenridge AM J Pharm Pharmacol; 1991 Sep; 43(9):650-4. PubMed ID: 1685525 [TBL] [Abstract][Full Text] [Related]
60. Comparison of disposition parameters of quinidine and quinine in the rat. Watari N; Wakamatsu A; Kaneniwa N J Pharmacobiodyn; 1989 Oct; 12(10):608-15. PubMed ID: 2630631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]